Most investors think in terms of "good stock" or "bad stock." That binary is too simple and too often wrong. A stock can have excellent fundamentals and still lose money for two years. A stock can have a weak balance sheet and still triple in twelve months. The reason is archetype.
Every stock falls into a recognizable pattern. That pattern is driven by the combination of its performance record, its fundamental health, its risk level, and its short-term price trend. Stoxcraft formalizes these patterns into four core archetypes. Once you can spot them, you stop reacting and start making decisions with context.
The four stock archetypes and how Stoxcraft identifies them
Stoxcraft tracks over 3,400 stocks across 156 industries using a multi-dimensional scoring system. Each stock receives scores across six dimensions: Performance, Health, Risk, trend direction, entry signal, and an overall star rating. The way those scores combine reveals the archetype. The Stoxcraft scoring system breakdown explains each dimension in full.
The four archetypes below cover the patterns you will encounter most often. Each one calls for a different response. Treating them the same is one of the most expensive mistakes investors make.
Momentum play: high reward, high burn rate
A momentum play is defined by one thing above all else: price has run far ahead of everything else. The performance record is strong. The short-term trend is surging. The risk score is elevated. These stocks are exciting to own when they are working and brutal when they stop.
What the momentum play score pattern looks like
The archetype shows up clearly in the data. A momentum play typically combines:
- A high Performance Score reflecting strong multi-year returns relative to peers
- A surging or climbing trend direction, with RSI extended, MACD positive, and the stock trading near its 52-week high
- A high Risk Score driven by elevated beta, a wide drawdown range, or both
The Risk Score in Stoxcraft works inversely to all other scores. A high number means high risk. This always needs to be stated clearly. Momentum plays almost always carry Risk Scores above 7.0 out of 10.
Palantir as the live momentum play example
Palantir Technologies (PLTR) is the clearest current example. The business keeps delivering. Q1 2026 revenue came in at $1.63 billion, up 85% year over year, with net income surging 307% versus the same quarter in 2025. Its Rule of 40 score, combining growth rate and free cash flow margin, stands at 127%. That number at this revenue scale is genuinely rare.
But the stock also delivered a three-year run producing over 1,000% in total returns. That performance history creates a specific tension. Over the past 12 months, PLTR underperformed the S&P 500, returning roughly 7% against the index's 24% gain. The stock hit its all-time high of $207.52 in November 2025 and has not recovered since.
The short-term trend turned negative. The MACD dropped below zero. RSI moved out of extended territory. That is the core tension in every momentum play: the business is still growing, but the timing signal has reversed.
The risk of chasing momentum plays
Much of the optimism around PLTR's future growth may already be priced in. The business quality is not in question. The valuation reflects every optimistic scenario. When sentiment shifts, even temporarily, the elevated Risk Score predicts what happens next.
Momentum plays are not stocks to avoid. They are stocks to size and time carefully. Entry timing matters more here than in any other archetype.
Quality compounder: the slow builder that consistently wins
The quality compounder is the opposite of the momentum play. It does not produce spectacular single-year returns. It does not generate heat on social media. What it does is compound quietly over many years, building wealth for investors who stay patient.
What the quality compounder score pattern looks like
The archetype has a distinctive signature. A quality compounder typically combines:
- A high Health Score reflecting strong fundamentals relative to its sector
- A medium Performance Score reflecting steady above-average returns without extreme peaks
- A low Risk Score meaning low volatility, low beta, and manageable drawdowns
These stocks rarely appear on momentum watchlists. The diversification they add to a portfolio often matters more than any single year's return.
Cboe Global Markets as the live quality compounder example
Cboe Global Markets (CBOE) fits this archetype precisely. It holds high fundamental quality, a solid long-term performance record, and a low risk profile. This pattern describes businesses with durable structural advantages that compound quietly without requiring a market crisis.
CBOE earns more per options contract each year as its product mix shifts toward higher-margin index options. Data revenue grows independently of whether fear rises or fades. The business is positioned to perform in most market conditions. Adjusted EPS hit $3.70 in Q1 2026, up 48% year over year. That kind of consistent earnings delivery, without dramatic stock price swings, is the quality compounder in action.
Why quality compounders get overlooked
Quality compounders rarely generate urgency. Nobody is calling them the next 10x stock. The short-term trend is often neutral or gently rising, not surging. The entry signal points to a moderate setup, not an urgent one. That combination keeps retail investors away and keeps institutional money flowing in quietly over time.
The advantage of owning one is straightforward. A quality compounder with a Risk Score below 3.0 out of 10 will not keep you awake the way a momentum play will. The volatility stays low, and the compounding does its job without drama.
Value trap warning: great business, terrible timing
This is the most dangerous archetype for investors who rely exclusively on fundamental analysis. The value trap looks compelling on every financial metric. Revenue is solid. Margins are healthy. The balance sheet is clean. But the price keeps going down, or sideways, while everything else rallies.
What the value trap score pattern looks like
The value trap warning has one of the most specific fingerprints in the Stoxcraft system. It combines:
- A high Health Score confirming genuine fundamental strength
- A low trend direction score, with a falling or crashing technical signal
- A low entry signal, meaning neither technicals nor analyst consensus supports a near-term reversal
The trap is buying on the Health Score alone. Fundamental strength is real. The timing is not.
Salesforce as the live value trap warning example
Salesforce (CRM) is a textbook case. It runs one of the strongest businesses in enterprise software. Its Health Score sits at 7.0 out of 10, placing it top tier within its sector. The company is growing. Its Agentforce AI platform is gaining traction. Its balance sheet is not broken.
But the stock has lost roughly a third of its valuation in 2026. CRM has lost 32% year to date while the Nasdaq 100 has risen 19%, one of the starkest divergences between business quality and price performance among large-cap software names. The MACD is generating a strong sell signal. The weekly RSI sits in the low 40s, weak enough to show deterioration but not yet oversold enough to signal a floor.
No oversold signal means no floor. No floor means no reversal catalyst from the technical side. Business quality cannot rescue entry timing when the trend has this level of bearish alignment.
How to avoid the value trap
The rule is simple: never act on the Health Score alone. A high Health Score tells you the business is strong. It does not tell you the market is ready to reward that strength. Wait for the trend direction to show at least a stabilizing signal before using fundamental quality as a buy reason.
Turnaround candidate: the low point that turns into an opportunity
The turnaround candidate demands the most patience and carries the clearest reward when the thesis plays out. These stocks have been weak. Performance has lagged. But the short-term technical picture is beginning to recover, and the entry signal is pointing to favorable timing.
What the turnaround candidate score pattern looks like
Turnaround candidates are identified by a specific combination:
- A low Performance Score reflecting recent underperformance versus peers and benchmarks
- A rising or climbing trend direction showing the technical picture is beginning to shift
- A high entry signal reflecting analyst upgrades, RSI near neutral or oversold recovery, or price approaching a favorable buy window
The signal is not confirmation that the turnaround is complete. It is confirmation that the setup is forming.
Hims and Hers Health as the live turnaround candidate example
Hims and Hers Health (HIMS) is the current live example from the Stoxcraft universe. The stock was down more than 25% year to date earlier in 2026. The Performance Score reflected that weakness directly.
Then the picture shifted. Shares surged 48.3% in the space of seven days, fueled by a combination of favorable regulatory signals, a renewed pharmaceutical partnership, and upgraded Wall Street sentiment. The technical signals that had been bearish started to reverse. HIMS moved back above its 20-day and 50-day moving averages. RSI climbed to 59.58. Both readings pointed to building bullish momentum.
The trend direction shifted from falling to rising. The entry signal moved from weak to favorable. That combination, a stock rebuilding its trend from a low base with improving analyst consensus, is exactly what the turnaround archetype describes. See the full Stoxcraft data on HIMS.
The risk inside turnaround candidates
A rising trend does not mean the bottom is confirmed. It means the signal is improving. Turnaround candidates carry more uncertainty than quality compounders and more upside potential when the thesis is correct. The risk is that the trend reverses again before the business recovery is established. Position sizing matters more here than in any other archetype.
How to use archetypes in your portfolio decisions
Knowing the archetype changes what questions you ask about each stock. Here is how to apply each one practically:
- Momentum play: ask whether the trend is accelerating or cooling. If RSI is falling from an extended level and MACD has crossed negative, momentum is fading. Size accordingly.
- Quality compounder: ask whether the Health Score has held up over multiple quarters. If it has, the compounding thesis is intact regardless of short-term noise.
- Value trap warning: ask what the catalyst is that closes the gap between fundamental strength and price weakness. If there is no clear catalyst, the setup is not complete.
- Turnaround candidate: ask whether the rising trend has been confirmed across multiple signals. RSI recovery, MACD crossing positive, and analyst sentiment improving together create a much stronger setup than any single signal alone.
Use the Stoxcraft stock screener to filter by score combinations and find stocks matching each archetype in real time across sectors.
What your current holdings reveal about your actual risk profile
Most portfolios, when audited using the archetype framework, reveal one of three problems. The first is concentration in momentum plays that the investor believes are quality compounders. The second is holding value trap warnings because the Health Score looks compelling. The third is missing turnaround candidates entirely because the recent performance history looks too weak to consider.
Running the Stoxcraft scores on each position takes less than five minutes. What those scores reveal often changes the conversation from "is this a good company?" to "is this the right archetype for my portfolio right now?"
The archetype does not replace your fundamental view of a business. It adds the timing and risk dimensions that most investors either skip or underweight.
Linde (LIN) sits near all-time highs with a beta of 0.15, one of the steadiest quality compounders in the industrial sector. Palantir (PLTR) sits at the opposite end with an elevated Risk Score and a trend that has cooled from its peaks. Salesforce (CRM) fits the value trap pattern, strong business and no technical floor yet in place. Hims and Hers Health (HIMS) is staging a turnaround that the short-term signals are starting to confirm.
None of these are buy or sell recommendations. They are pattern identifications. Stoxcraft Score based on FMP data. Knowing the pattern is what lets you ask the right question for each one.
Which archetype you own is the question that compounds
Four archetypes. Every stock you will ever own falls into one of them, at least temporarily. Momentum plays deliver fast. Quality compounders deliver consistently. Value traps look right but keep disappointing. Turnaround candidates reward patience when the setup is real.
The score combinations that define each archetype make the pattern visible without guesswork. Knowing which type of stock you are holding does not guarantee the right outcome. It does guarantee that you are asking the right questions before you decide.
